96 related articles for article (PubMed ID: 2891480)
1. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.
Spearman ME; Goodwin RM; Kau D
Drug Metab Dispos; 1987; 15(5):640-7. PubMed ID: 2891480
[TBL] [Abstract][Full Text] [Related]
2. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys.
Lindstrom TD; Althaus WA; Ruterbories KJ; Kau D
J Pharmacol Exp Ther; 1990 Mar; 252(3):1117-24. PubMed ID: 2319463
[TBL] [Abstract][Full Text] [Related]
4. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas.
Schneck D; Butler F; Dugan W; Littrell D; Petersen B; Bowsher R; DeLong A; Dorrbecker S
Clin Pharmacol Ther; 1990 Jan; 47(1):36-41. PubMed ID: 2295217
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
Apelgren LD; Zimmerman DL; Briggs SL; Bumol TF
Cancer Res; 1990 Jun; 50(12):3540-4. PubMed ID: 2340502
[TBL] [Abstract][Full Text] [Related]
6. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.
Petersen BH; DeHerdt SV; Schneck DW; Bumol TF
Cancer Res; 1991 May; 51(9):2286-90. PubMed ID: 2015593
[TBL] [Abstract][Full Text] [Related]
7. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
[TBL] [Abstract][Full Text] [Related]
8. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory.
Roy ML; Pikal MJ; Rickard EC; Maloney AM
Dev Biol Stand; 1992; 74():323-39; discussion 340. PubMed ID: 1592182
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.
Apelgren LD; Bailey DL; Briggs SL; Barton RL; Guttman-Carlisle D; Koppel GA; Nichols CL; Scott WL; Lindstrom TD; Baker AL
Bioconjug Chem; 1993; 4(2):121-6. PubMed ID: 7873643
[TBL] [Abstract][Full Text] [Related]
10. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
[TBL] [Abstract][Full Text] [Related]
11. KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.
Bumol TF; Baker AL; Andrews EL; DeHerdt SV; Briggs SL; Spearman ME; Apelgren LD
Targeted Diagn Ther; 1988; 1():55-79. PubMed ID: 2979063
[No Abstract] [Full Text] [Related]
12. Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB.
Riggin A; Clodfelter D; Maloney A; Rickard E; Massey E
Pharm Res; 1991 Oct; 8(10):1264-9. PubMed ID: 1796044
[TBL] [Abstract][Full Text] [Related]
13. Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys.
Colletti AE; Krieter PA
Drug Metab Dispos; 1994; 22(2):183-8. PubMed ID: 8013272
[TBL] [Abstract][Full Text] [Related]
14. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
15. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.
Laguzza BC; Nichols CL; Briggs SL; Cullinan GJ; Johnson DA; Starling JJ; Baker AL; Bumol TF; Corvalan JR
J Med Chem; 1989 Mar; 32(3):548-55. PubMed ID: 2783975
[TBL] [Abstract][Full Text] [Related]
16. Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.
Lelievre E; Guillaudeux J; Cardona H; Bourguignat A; Lokiec F; Solere P; Lucas C; Sauveur C
Cancer Res; 1993 Aug; 53(15):3536-40. PubMed ID: 8339259
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
18. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.
Siefert HM; Maruhn D; Maul W; Förster D; Ritter W
Arzneimittelforschung; 1986 Oct; 36(10):1496-502. PubMed ID: 3814211
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine in rats, dogs, and monkeys.
Hucker HB; Hutt JE; White SD; Arison BH; Zacchei AG
Drug Metab Dispos; 1983; 11(1):54-8. PubMed ID: 6132797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
